



*Accelerating
the
Search
for a
Cure*

**INSIDE
THIS ISSUE**

Friends for Life Gala
Page 2

Race for Research
Page 3-5

Families Funding
Research
Page 5

Senior Research
Awards
Pages 6 - 7

Clinical Trials
Monitor
Page 7

Medical Corner
Pages 8-9

Institutional Insights
Page 10

Ask the Expert
Page 11

Industry Update
Page 12

Advocacy Update
Page 13

Research
Roundtable
Page 14

Meet the Board
Page 15

Annual Appeal
Donors
Page 16-19

Calendar
Page 19

MYELOMA FOCUS

Newsletter of the

MMRF

Yankees Support MMRF in NYC Ortho Biotech & Dr. Jagannath Honored

On Monday, June 9th, New York Yankee pitching coach, Mel Stottlemyre, and his wife Jean hosted the Multiple Myeloma Research Foundation's third annual New York City Awards Dinner at the St. Regis Hotel, raising over \$400,000 for myeloma research. Mr. Stottlemyre, Honorary MMRF Board Member and myeloma patient, along with his wife Jean have become advocates for those affected by blood cancers and have devoted their lives to "striking out cancer" through the Mel Stottlemyre Foundation.



Fellow MMRF Honorary Board Members, Geraldine Ferraro and Ann Curry, who served as the event's master of ceremonies, were on hand to welcome the corporate and medical leaders who filled the ballroom to honor Ortho Biotech, L.P. (one of the world's leading bio-technical companies) and Dr. Sundar Jagannath (Chief of the Multiple Myeloma Center at St. Vincent's Comprehensive Cancer Center).

Ortho Biotech, a subsidiary of Johnson & Johnson, received the **MMRF Corporate Leadership Award** for their ongoing commitment to improving the quality of life of cancer patients world wide. As a global organization with passion for the constituents they serve, Ortho continually seeks new ways of meeting the needs of the health care community through new products, technologies, and programs. Carol Webb, Group Chairman of Johnson & Johnson and former President of Ortho Biotech, graciously accepted the award.



(L-R) Ann Curry, Dr. Sundar Jagannath
and Carol Webb

Dr. Jagannath, an MMRF Scientific Advisory Board member, was honored for his compassion and commitment to his patients. Dr. Jagannath received the **MMRF Humanitarian Award**, for his long-standing championship of novel therapy treatments and for being instrumental in advancing progress made in the search for a cure of myeloma. Presenting the award to Dr. Jagannath were two of his devoted patients, Mary Vinson-Blackwell and Angie Minnick.



Welcome Letter

Dear Friends,

There is no doubt that more and better myeloma therapies are available today as the direct result of a significant and steadily growing investment in myeloma research. The funding commitments and strong partnership of the MMRF, the pharmaceutical and biotech industries and the National Cancer Institute (NCI) have led to the continuous discovery of new treatments that are improving and extending the lives of myeloma patients.

It is our belief that this progress can continue.

We are acutely aware that the National Institutes of Health's (NIH) budget will remain level and that the NCI will not be able to grow its investment in blood cancer research in the coming year. This means that it will be increasingly the job of philanthropy to risk-share with the pharmaceutical industry in order to ensure continued progress in myeloma research. With your help, the MMRF is fully prepared to take on this charge. Your support is critical, but the pace of progress can be maintained.

We look forward to our continued partnership with the pharmaceutical industry and the NCI to bring new treatments to trial and to market. As patients and partners in the fight to cure myeloma, we must all step up to ensure research progresses, treatments evolve and that the lives of patients continue to improve. Please help us keep up the needed pace with your efforts and contributions.



Sharon Osbourne, Pepsi to be highlighted at MMRF Fall Gala

The Multiple Myeloma Research Foundation returns to the Hyatt Regency in Greenwich, CT to host their 7th annual "Friends for Life" Fall Gala. The event will be held on Saturday, October 25th and will raise awareness and funds for multiple myeloma research. Receiving the MMRF Spirit of Hope Award will be Sharon Osbourne. Ms. Osbourne, a cancer survivor who recently started her own charitable foundation, has done a great deal to raise awareness of cancer since her diagnosis 14 months ago. Though a fixture on late night television, Ms. Osbourne will soon star in her own daytime talk show, "The Sharon Osbourne Show". The show premieres on September 15th nationwide on the WB network.



This year's Gala promises to be a spectacular and fun-filled evening. Dave Burwick, Chief Marketing Officer at Pepsi-Cola North America, will serve as the Gala's Corporate Chairman. Mr. Burwick oversees the \$4 billion refreshment beverage unit of PepsiCo, Inc. in the U.S. and Canada and has been with Pepsi for 13 years. Mr. Burwick, aided by Lori Marcus and some of his top department leaders, will spearhead efforts to raise over \$1 million for myeloma research.

Joining Mr. Burwick on the Gala leadership team will be several executives from some of the nation's top companies - Time, Inc., U.S. Surgical, Jones Apparel Group, Merrill Lynch, KPMG, UBS and others. Also supporting the event will be Honorary Gala Chairs, Ann Curry, news anchor of *Today*, and Geraldine Ferraro, former vice-presidential candidate and myeloma patient. Emceeding the event for the fifth time will be Deborah Norville. Deborah, an MMRF Honorary Board Member, is a two-time Emmy winner and host of the top-rated newsmagazine, *Inside Edition*.



For sponsorship information, please contact Craig Robertson, MMRF Director of Development, at (203) 972-1250 or robertsonc@themmrff.org

MMRF RACE FOR RESEARCH 5K Walk/Run

1st Annual Boston MMRF Race for Research Captures the Spirit

The first annual MMRF Race for Research - Boston, held April 27th on the beautiful Charles River Esplanade, was a hugely successful event. Nearly 1,000 participants helped brighten the skies over the Bay State on an otherwise dreary day. Over \$160,000 was raised to fund the most cutting-edge myeloma research.

A heartfelt thank you goes out to our flagship sponsor, Millennium Pharmaceuticals, Inc., as well as to our event chairmen, Dr. Kenneth Anderson, Director of the Jerome Lipper Multiple Myeloma Cancer Center, Ron Burton, former New England Patriot and to Mark Levin, CEO of Millennium Pharmaceuticals. We would also like to recognize the tremendous team effort put forth by the Millennium team. In total, over 200 Millennium employees showed their support by participating in the event and helped to raise additional funds for myeloma research.

The MMRF would also like to thank the following companies and individuals who helped support the inaugural event: Jordan's Furniture, New Balance, NFL Alumni New England Chapter in Memory of Don Allard, Reebok, Steve Burton, Ruth Budelmann & Family, Marc Cohen, Laurie Coppola &



(L-R) Ron Burton, Mark Levin, Kathy Giusti and Dr. Ken Anderson

Family, Dr. Mel Goldstein, Diane Moran, John McNeice, Jr., Kevin Klett, Samara Krugman & Friends, New England Area Multiple Myeloma Support Group, A. Raymond Tye and to William White.



Dr. Ken Anderson (center) pictured with top Boston Race fundraisers, Barbara and Steve Goldfingers



The Millennium Pharmaceuticals Team
Boston 5K Walk/Run

MMRF RACE FOR RESEARCH 5K Walk/Run

2nd Annual Seattle MMRF Race for Research A Big Success

The second annual MMRF Race for Research – Seattle, held July 19th, at Sand Point – Magnuson Park, was once again a huge success. Over 650 registered walkers and runners came out on a spectacular sunny morning to support the MMRF. In addition to raising a great deal of awareness and having a great time, event participants and sponsors helped raise over \$125,000 for myeloma research. A very special thank you goes out to our flagship sponsors, Schwartz Brothers Restaurants and Cell Therapeutics, Inc. (CTI), as well as to our event chairmen, Dr. James Bianco, CEO of CTI, Stacy Schwartz and to Jeff Nelson, Pitcher for the Seattle Mariners.

The MMRF would also like to send a very special thank you to the family of John Schwartz, a local Seattle businessman who lost his battle with myeloma this past January. The Schwartz family played an integral role in the success of the event again this year and has continued to be remarkably dedicated to fighting this disease.

We are extremely appreciative of our event sponsors for their dedication and generosity -- NeoRx, Starbucks, Benaroya Company, Charlie's Produce, Chandler's Crabhouse, Service Linen Supply, Dr. Bob Bjurstrom, Stusser Family, Sam Shain Foundation, GreenButton Technologies, Catalyst Marketing, LaCount Marketing Group, 24 Hour Fitness and to the "John's Aunt Rose" team.



Schwartz Family and Friends



The Team from Seattle Genetics



(L-R) Karen Larsen, Kathy Giusti, Stacy Schwartz

UPCOMING SCHEDULE Race for Research 5K Walk/Run

Sunday, September 14, 2003
Chicago, IL

10:00AM - Grant Park
(Randolph & Lakefront)

Event Chairs include:

- Dr. Seema Singhal, Director
Myeloma Program, Northwestern University
- Dusty Baker, Manager Chicago Cubs
- Senator Dick Klemm

Sunday, October 5, 2003
Atlanta, GA

9:00 AM - Piedmont Park

Event Chairs include:

- Dr. Leonard Heffner, Assoc. Prof. of
Hematology & Oncology at Winship Cancer
Institute, Emory University
- Hamilton Jordan former White House
Chief of Staff
- Oscar Gamble former NY Yankee

Sunday, November 16, 2003
Washington, D.C.

8:00 AM - West Potomac Park

Event Chair:

Senator Kay Bailey Hutchison

For more information about upcoming races,
contact Shelley Christie at
Christies@themmr.org,
or visit the MMRF's website at
www.multiplemyeloma.org/events

Families Funding Research



The Young Family and Friends

Tim Young wrote a promise to his father on a Christmas card two years ago. It was a pledge to honor him always and to keep hope alive for thousands of patients and families affected by multiple myeloma. At that time, Tim's father was losing his battle against the disease. He passed away shortly after the New Year, but Tim knew he still had to give him a Christmas present.

Tim decided to turn his promise to his father into an event that would bring people together to enjoy one of his dad's favorite pastimes and raise money to support myeloma research. A golf outing at the Burden Lake Golf Course in his family's upstate New York hometown -- the last course he and his dad played together -- would be the most fitting tribute.

With the help of his family, including his brothers Dave and Tony, his mother Joan and several friends, the golf outings they have hosted have been very successful. This year's second annual tournament raised over \$10,000 for the MMRF and Tim has plans to keep it growing. "We plant seeds all year round to get the word out. This year I recruited each participant to be a part of the tournament committee, and asked each of them to get others involved."

We think it's safe to say that everyone walked away a winner in support of the cause. As for Tim and his promise to his father, we think he shot a hole in one!

The Third Annual Young Memorial Golf Tournament
will be on June 26, 2004.

For more information contact Tim Young at
tbbyoung@aol.com

MMRF Senior Research Awards

The MMRF Awards \$900,000 in Senior Research Grants

The MMRF is proud to announce the nine recipients of the 2003 Senior Research Awards, each of whom will receive \$100,000 to conduct one year of cutting-edge research. These world-renown researchers represent the top 30% of grant applications submitted this grant cycle, and their projects predominantly focus on the identification and testing of new targets and therapies for myeloma. The MMRF is committed to accelerating the search for a cure through funding the world's most promising research, and by year end, the MMRF will have awarded more than \$16 million to myeloma research, including \$5 million this year alone.



Nancy Krett, PhD
Northwestern University

Glucocorticoids (Decadron or Prednisone) are among the most effective agents for the treatment of multiple myeloma. These steroids kill myeloma cells but the mechanism of action needs to be better characterized. The expression of a spectrum of genes is regulated by glucocorticoids and appears to play a critical role in promoting cell death. GILZ (glucocorticoid-induced leucine zipper) appears to be one of the central molecules in this pathway and its role will be dissected in this project.



Bharat Aggarwal, PhD
University of Texas
M.D. Anderson Cancer Center

Almost 90% of myeloma patients eventually develop resistance most likely due to a defect in cell death mechanism. We propose the use of curcumin, a turmeric component, to overcome resistance. We have shown that curcumin inhibits activation of NF-kB and induces cell death in MM cells. Based on these studies, we propose to determine potential mechanisms of chemoresistance in MM cells and to determine if curcumin can reverse the resistance to dexamethasone, melphalan and doxorubicin in MM cells.



Klaus Podar, MD, PhD
Dana-Farber Cancer Institute

"Lipid raft" microdomains within the myeloma cell surface function as platforms for regulating tumor cell growth and movement in the bone marrow. I will test whether these structures are essential for MM cell growth, survival, drug resistance and migration. By investigating the mechanisms whereby lipid rafts modulate these effects, the proposed studies aim to identify new treatment targets within the MM cell surface to overcome resistance to conventional therapies.



Hans Johnsen, MD, DMSc
Herlev University Hospital

It is the hypothesis of this research that a myeloma hierarchy exists, which includes chemo-resistant progenitors identified as oncogene positive memory B cells. These cells present in blood, marrow and lymph node are potential malignant dormant "myeloma stem cells", which may be responsible for and feed posttransplant disease recurrence. The clinical impact of these cells is at present unknown and needs to be studied by analyzing the toxicity, safety and efficacy of highly selected targeted therapy.



Jonathan Schneck, MD, PhD
Johns Hopkins University School of Medicine

Adoptive immunotherapy involves stimulation of tumor-specific T cells ex vivo, followed by transfer of expanded numbers of activated T cells back into patients. We propose to use an engineered artificial Antigen Presenting Cell (APC) with the goal of replacing the use of autologous dysfunctional APC for adoptive immunotherapy for multiple myeloma. Therefore, the work proposed in this application will enable advances in adoptive immunotherapy for treatment of multiple myeloma.

Senior Awards Cont'd



Keith Stewart,
MB. CHB, F.R.C.P.C., MBA
Princess Margaret Hospital,
University Health Network

Current genomic technologies now allow studies of thousands of genes in a single experiment. When data from all of these genes are compiled from several patient samples, a molecular signature of a disease can be generated. Recently, using such a strategy, we have identified a pathway that is activated in cells under stress, such as myeloma. We wish to explore further whether novel therapeutic targets in myeloma can be identified and whether improved therapeutic strategies can be designed based on this discovery.



Jonathan Stuart Wall, PhD
University of Tennessee Graduate
School of Medicine

Primary (AL) amyloidosis is a B-cell cancer related to multiple myeloma and characterized by the accumulation in tissues of protein aggregates composed of antibody-related components. Unfortunately, there are no effective therapies for patients with this disease. Our

proposed method for discovering new therapeutic drugs to treat AL amyloidosis is to test a large number of chemical compounds supplied by the NCI for their ability to hinder or inhibit the disease.



Karin Vanderkerken, PhD
Free University of Brussels and
Peter Croucher, PhD
University of Sheffield Medical
School

To study multiple myeloma and develop new treatments for this disease, animal models are required that accurately reflect the disease in humans. One series of models has been shown to mimic the human disease, however, these models are not widely available. We are proposing to establish a core facility in Brussels, based jointly in the laboratories of Dr. Croucher and



Dr. Vanderkerken to maintain these models and make them available for researchers interested in the biology and treatment of myeloma.

Clinical Trials Monitor

To date, more than 18,000 visitors have accessed multiple myeloma clinical trials through the MMRF's Clinical Trials Monitor (CTM). CTM has the most comprehensive listing of myeloma clinical trials found anywhere, and new trials and sites are added weekly. You can easily search for myeloma trials according to type of treatment, patient type and geographic location. The following are samples of trials currently posted on CTM:

Phase III randomized trial of thalidomide plus zoledronic acid (Zometa) versus zoledronic acid alone in patients with early stage multiple myeloma.

Phase II study of arsenic trioxide (Trisenox) in combination with ascorbic acid (vitamin C) and dexamethasone (TAD) in patients with relapsed/refractory multiple myeloma.

Phase II trial of PS-341 (Velcade) alone and in combination with dexamethasone in previously untreated multiple myeloma patients.

Log on to www.myelomatrials.org today to find the trial that is right for you or your patients. For more information, contact Anne Quinn Young, Program Director, at quinnyoung@themmr.org

MEDICAL CORNER

Update on NCI Funding for Myeloma Research

The National Cancer Institute (NCI) is the Federal Government's principal agency for cancer research, supporting and coordinating projects through grants and cooperative agreements. The NCI currently funds:


- ◆ 34 Research Project (R01) grants, awarded to institutions to allow Principal Investigators to pursue a single research objective.

- ◆ Six Research Program (P01) Projects, integrated, multi-project programs that have a focused theme and involve several investigators.


- ◆ A recently initiated Specialized Program of Research Excellence (SPORE) in myeloma, which promotes interdisciplinary research and helps move basic research findings from the bench to the bedside (see page 9).

The NCI's investment in myeloma research increased from \$6 million in 1990 to \$20.8 million in 2002 (chart above). However, 2002 myeloma funding represented only 0.5% of the total funding for cancer, and this percentage is expected to decline in the years ahead, so there is still more to be done to increase myeloma funding. In 2002, the MMRF awarded an unprecedented \$4 million in funding and is committed to provide \$5 million this year to help move myeloma research forward.

NCI Funding (\$MM)



MMRF Commitment to Research



What Is The LLM PRG?

The LLM PRG is a panel of prominent scientists, physicians and advocates charged with assessing the state of the science for leukemia, lymphoma and myeloma and making recommendations for future research. Kathy Giusti served as an advocacy representative for this PRG, MMRF Scientific Advisors Ken Anderson and Bart Barlogie were co-chairs and Bill Dalton and many others served on the myeloma panel.

Priority Areas for Research

In 2000, the NCI established a Leukemia, Lymphoma and Myeloma Progress Review Group (LLM PRG, see box) to identify gaps in our understanding of these disorders, barriers to progress and key research priorities. The LLM PRG released a comprehensive report of their findings in 2001 and identified the following priority areas for research:

- ◆ Creation of a Cancer Translational Research Allied Consortium (C-TRAC) to help shorten drug development time through a novel alliance among academia, industry, government and patients.
- ◆ Hasten drug development and clinical trials and fostering collaboration.
- ◆ Further investigate the biology of the disease.
- ◆ Increase education and training and investigate ways to identify high-risk patients.
- ◆ Understand the potential causes of myeloma.

In October 2002, the NCI prepared a strategic plan for addressing these recommendations. Although some are now being implemented, the focus of the MMRF will be to partner with NCI to ensure all priorities are implemented.



MEDICAL CORNER

NCI Initiates Myeloma SPORE Specialized Program of Research Excellence

The MMRF congratulates the NCI on its initiation of a Specialized Program of Research Excellence (SPORE) in myeloma. Through the SPORE, the NCI will provide \$12 million over a course of 5 years for cutting-edge myeloma research. Ken Anderson of the Dana-Farber Cancer Institute will be Director of the program.

According to Dr. Anderson, “The overall theme of the myeloma SPORE is to identify and evaluate novel targeted therapies, with the goal of translating biological and technological advances into improvements in diagnostics, predictors of outcome and advances in treatment.” The SPORE will consist of five research projects:

- ◆ Novel therapies that target the proteasome, a pathway important in tumor cell growth and survival.
- ◆ Targeting telomerase, an enzyme that aids tumor survival.
- ◆ Targeting the MUC-1 pathway, which is important in tumor survival.
- ◆ Novel therapies that target genetic abnormalities in myeloma.
- ◆ Molecular markers that identify progression from MGUS to myeloma.

Each project will have a major emphasis on translation of research from the lab to the bedside, and conversely, will take samples from patients back to the lab to determine whether the clinical results correlate with the lab data. Together, this will lead to improved prognostic strategies and therapies for myeloma.




Dr. Ken Anderson

Although based at Dana-Farber, the SPORE represents a collaborative effort between myeloma research groups at Dana-Farber and two other Harvard institutions, as well as the Mayo Clinic, Cornell University Weill Medical College and the Moffitt Cancer Center. “The program represents the integrated efforts of institutions with a unique and long track record of basic and clinical expertise in myeloma, notes Dr. Anderson. “We’ll now work together to more rapidly move novel targeted therapies from the laboratory to the clinic to improve patient outcome.”



Webcast from the IXth International Myeloma Workshop

A webcast from this year’s IXth International Myeloma Workshop, held in Salamanca, Spain, is now available on the MMRF homepage at www.multiplemyeloma.org. This webcast features international myeloma experts covering the latest cutting-edge research from this biennial international workshop, which brought together more than 1,000 researchers to discuss the scientific progress made in the experimental, clinical and therapeutic areas of multiple myeloma.



MMRF INSTITUTIONAL INSIGHTS

Dr. Sundar Jagannath chaired the MMRF Institutional Insights program in New York City on June 20, 2003. Partnering with the Saint Vincent's Comprehensive Cancer Center, the MMRF was excited to have brought over 300 patients and professionals the latest research and treatment information on multiple myeloma, including updates from the IXth International Workshop on Multiple Myeloma (Salamanca, Spain) and American Society of Clinical Oncology (Chicago, IL). Drs. Kenneth Anderson, James Berenson, William Bensinger and Mohamad Hussein joined Dr. Jagannath presenting on disease biology and staging, contemporary therapies, stem cell transplantation, novel therapies and current clinical trials.



Dr. Jagannath
Program Chair

The patient program was interactive, with the audience having the opportunity to ask the experts questions. The **Ask the Expert** section of this newsletter is based on the questions from the patient symposium. Included in the program was also the computer response system technology to quiz participants about each topic discussed. The speakers were very impressed that at the end of each session patients answered the treatment questions correctly!

The professional program also utilized the audience response technology. The participants were from academic or teaching institutions (54%) and community practice (46%). The demographic responses showed many had recently completed their oncology training (35% completed less than 5 years ago), and over 25% of the audience has been practicing for more than 20 years.

The MMRF would like to thank all of the speakers for their time dedicated to, and in support of, our programs. If you wish to receive the handouts from this or other Institutional Insight programs, please contact the MMRF.



Dr. Bensinger speaking to a full house

Upcoming Institutional Insight Programs

October 2 - 3, 2003

Toronto, Ontario

Novel Therapeutic Approaches in the Treatment of Multiple Myeloma: A collaborative program brought to you by the MMRF, University of Toronto, and the McCarty Cancer Foundation.

November 5 - 6, 2003

Chicago, IL

Institutional Insights Physician and Patient Seminars. Jointly Sponsored by MMRF, LRF and Robert H. Lurie Comprehensive Cancer Center of Northwestern University

November 13 - 14, 2003

Tampa, FL

Novel Therapeutic Approaches in the Treatment of Multiple Myeloma: A collaborative program brought to you by the MMRF and H. Lee Moffitt Cancer Center & Research Institute

For more information, please call Sara Nichols, Program Coordinator at (203) 972-1250 or email at nicholss@themmrf.org. Online registration is available at www.multiplemyeloma.org/events

ASK THE EXPERT



Dr. Douglas Joshua

This issue's Ask the Expert features the MMRF's Scientific Advisor, Douglas Joshua, MBBS, DPhil. Dr. Joshua is Professor of Medicine at the University of Sydney and Head of the Institute of Hematology at Royal Prince Alfred Hospital, Camperdown, Australia.

Dr. Joshua, with regard to long-term survival, how important is it to achieve a complete response?

In general, the achievement of a complete response (CR, see box below) is an important factor that contributes to increased likelihood of long-term survival compared with achievement of a lesser response. This is true of high-dose chemotherapy and stem cell support, where a CR is associated with long-lasting disease control and prolonged survival, as well as other treatment regimens, regardless of the number of treatments by which it is achieved.

What is a Complete Response?

In general practice, a Complete Response (CR) is defined as having:

- ◆ No detectable M protein in the serum and
- ◆ A normal percentage of plasma cells in the bone marrow or absence of myeloma cells by staining techniques

However, more stringent criteria are being used more frequently to determine response to therapy in clinical trials.

But perhaps more importantly, there is dramatic difference in the quality of life experienced by patients who achieve a CR compared with those who do not. Achievement of a CR signifies cessation of disease progression and a return to 'normal' living.

For patients who have achieved a complete response or very good partial response with just minimal residual disease (MRD), what might be recommended for maintenance therapy besides bisphosphonates? Could Velcade™ (Millennium Pharmaceuticals, Inc.) or CC-5013 (Celgene) be used in a maintenance setting?

Outside of a clinical trial, options for maintenance therapy include steroids or interferon. In clinical practice, most patients with MRD receive alternate-day prednisone or a similar form of steroid, which appears to increase the length of progression-free and overall survival. Interferon is now less often used as maintenance therapy, mainly due to its poor tolerability, cost and minimal impact on survival.

The use of some of the newer anti-myeloma drugs, which have shown dramatic results in relapsed and refractory disease, must be evaluated as part of properly conducted controlled Phase III trials before they can be recommended as maintenance therapy. This is mainly because giving a drug with potential side effects to a patient who is well and in remission is quite different than giving the drug to a patient who has active disease, where the benefits clearly outweigh the potential risks. A drug's benefits in the maintenance setting must also outweigh any potential risks.

Thalidomide (Thalomid® ,Celgene) is currently being investigated as maintenance therapy in several large clinical trials, including our own Australian National Study, where it is given in conjunction with the bisphosphonate zoledronic acid (Zometa®, Novartis). Early data should be available next year. Thalidomide in combination with prednisone is also being evaluated as maintenance therapy in a Canadian study.

The MMRF THANKS
Celgene and Novartis
Sponsors of
Myeloma Focus



INDUSTRY UPDATE

The MMRF is promoting awareness of two current myeloma trials of the promising oral immunomodulatory drug CC-5013 (Celgene).

Single-agent CC-5013 Phase II Trial Now Enrolling

Patients with relapsed and refractory myeloma now have the opportunity to receive single-agent CC-5013 as part of a Phase II open-label study. The multicenter study (014), which is evaluating the safety and efficacy of the single agent, is expected to enroll 200 patients.

To be eligible for the study, patients must have relapsed after having had at least stable disease or a partial response ($\geq 50\%$ reduction in M protein) to a previous therapy and have continued to develop disease progression despite salvage anti-myeloma therapy (treatment given if a patient does not respond to, or has relapsed after responding to, therapy). Patients must have progressed during their last therapy prior to study enrollment. Patients may have been previously treated with thalidomide and/or radiation, but cannot have received CC-5013 before. Patients can receive other standard or experimental myeloma therapy up to within 28 days of initiation of the study.



For each patient, the study will include a treatment phase and a follow-up phase. All patients who qualify for enrollment will receive oral CC-5013 (25 mg/day) in 28-day cycles for as long as they respond to therapy or achieve stable disease (see figure [below]). Study endpoints include response rate, the length of time before disease progresses and overall survival.

Enrollment Continues in CC-5013 Phase III Trial

The Phase III trial comparing CC-5013 and dexamethasone with dexamethasone in patients with previously treated myeloma continues to enroll patients. A total of 604 patients will be enrolled in the study, which includes identical US (009) and International (010) trials. Over 40 sites in the US and Canada are now open and a total of 105 sites will be enrolled worldwide.

Patients who have relapsed after one to three previous antimyeloma therapies are eligible for the study. Patients can have previously received high-dose dexamethasone (< 200 mg in a prior month) up to 6 months prior to study participation but must not be dexamethasone refractory.

The study consists of a treatment phase and follow-up phase. Patients will be randomized to receive CC-5013 (25 mg/day) and high-dose dexamethasone or an identically-appearing placebo and high-dose dexamethasone (see figure below). Patients achieving a response or stable disease will continue on therapy. The primary endpoint of the double-blind study is achievement of 50% improvement in time to disease progression.



For more information about these trials and available sites, see the MMRF's Clinical Trials Monitor www.myelomatrials.org

ADVOCACY UPDATE

Follow Up From Advocacy Day 2003



(L-R) Allan Bailey, Kathy Giusti and Senator Hutchison

The Multiple Myeloma Research Foundation (MMRF) and the Lymphoma Research Foundation (LRF) were pleased with the outcome of the third annual Blood Cancer Advocacy Day held in June, and are poised to continue the momentum.

Less than ten days after Advocacy Day, Senator Kay Bailey Hutchison secured \$5 million for blood cancer education, support and outreach from the Senate Appropriations Subcommittee on Labor, Health and Human Services and Education. These funds, once approved by both houses of Congress, will provide funds to the Geraldine Ferraro Cancer Education Program at the Centers for Disease Control and Prevention (CDC), part of the Hematological Cancer Research Investment and Education Act, which was signed into law following last year's Advocacy Day. The MMRF applauds Senator Hutchison's commitment to

increasing funds for blood cancer research and education. This success is one of many policy initiatives supported by the blood cancer community, and our work at the federal level continues. Some of our next steps are:

- ◆ Identify how to best appropriate funds the Geraldine Ferraro Cancer Education Program.
- ◆ Increase research funding.
- ◆ Continue efforts to secure funding from the Department of Defense as part of a special MMRF Task Force chaired by Bruce Holmberg.
- ◆ Keep advocates informed about the status of key legislation and ways that they can continue to influence these policies throughout the year.

Thanks to all of our advocates and congressional champions, we truly are making a difference!



Advocates storm the Hill on Advocacy Day

For more information on how to get involved as a blood cancer advocate, please contact: Anne Quinn Young at quinnyounga@themmrf.org.

Kathy Giusti Appointed to National Cancer Policy Board



MMRF Executive Director Kathy Giusti has been named to serve on the National Cancer Policy Board (NCPB), a multi-disciplinary panel convened by the Institute of Medicine and the National Research Council. During her 3-year tenure, Giusti will be involved in addressing policy issues facing the cancer community and will offer recommendations on strategic collaborations, research efforts and education initiatives aimed at combating cancer at a national level.

“I feel fortunate to have the opportunity to apply the knowledge I have gained as both a cancer patient and the leader of a research foundation to effect broad policy issues and advance the country's fight against all cancers,” said Giusti. “The NCPB includes a wide array of distinguished professionals and

I am honored to join them in this important effort.”

As a member of the NCPB, Giusti will be involved in assessing progress on initiatives, discussing emerging issues and gathering information from the private and public sector, including many federal and state agencies. The NCPB then makes recommendations regarding guidelines, resource allocations and strategic initiatives. The NCPB may commission papers and also holds workshops in support of recommendations and resulting projects.

In addition to her appointment to the NCPB, Giusti serves on the National Cancer Institute's Director's Consumer Liaison Group (DCLG) and is a member of the Cancer Leadership Council. She is also member of the Board of Directors for IMS Health.



YOU NEED TO KNOW

American Society of Hematology (ASH)
Dec. 5-9, 2003 - San Diego, CA

◆ **Webcast:** For the third consecutive year, the MMRF will webcast highlights from the Multiple Myeloma Education Session and cutting-edge oral and poster presentations at the ASH annual meeting.

We are delighted to have Dr. Barlogie chair the 2003 MMRF webcast, *Update from ASH*. The program will feature the latest information on myeloma and its treatments from the selected researchers who will be presenting at this prestigious meeting. Similar to past webcasts, *Update from ASH* will include live audio interviews, full transcripts of the interviews, key slides from the actual presentations, as well as citations to other peer-reviewed scientific articles. For the first time ever, the webcast will feature slides that are synchronized with each presentation so that you can listen to the interview and follow along with the slides.



Dr. Bart Barlogie

◆ **Teleconference:** On December 18th from 1:30-2:30 PM EST, the MMRF and CancerCare will bring you a live update from two leading myeloma opinion leaders who will have attended and presented research at the ASH meeting. You will have the opportunity to hear about the latest research on myeloma treatments and ask questions directly of these experts. More than 3,000 of you listened to the “*Update from the IXth International Myeloma Workshop*” in June. Mark your calendar — don’t miss out on this semi-annual event!

To all of the healthcare professionals -- this program works perfectly as a lunch and learn for you and your colleagues!

◆ **Winter / ASH Newsletter:** Check your mailboxes right after the December holidays for the *Myeloma Focus Newsletter*. This issue will feature leading international myeloma experts as guest editors who will share the most exciting and promising research that will be presented at the meeting.

Be sure to monitor upcoming issues of *SmartBrief* and www.multiplemyeloma.org for the latest updates and information.

Research Roundtable

Novel Targeted Therapeutics

Myeloma investigators from academia, the pharmaceutical industry and the National Cancer Institute (NCI) were brought together to share their expertise in innovative, targeted therapies at the MMRF Research Roundtable on Targeted Therapeutics. Research Roundtable was co-chaired by Kenneth Anderson, Jesús San Miguel, MD, PhD and Garreth Morgan, MD.

During the session, thought leaders discussed novel therapies that target the tumor site, interrupt various processes within the tumor cell, or target both the tumor and its environment. The roundtable was unique in that it paired presentations by pharmaceutical investigators with those of clinical investigators.

According to Dr. Morgan, there was a consensus that, with these targeted therapies, novel strategies for evaluation must also be developed. These strategies include endpoints other than survival, such as those that can show a drug prevents disease progression or ‘switches off’ the cellular pathway of interest. “This would make it easier to evaluate single agents and help understand how they may be used in combination,” he noted.

“The roundtable offered scientists from academia and industry an opportunity to share new cutting-edge information, as well as to plan collaborative preclinical studies and treatment protocols using novel agents alone and in combination,” noted Dr. Anderson.

The meeting proceedings are pending publication in *The Haematology Journal*, the official journal of the European Haematology Association.



(L-R) Anne Quinn Young, Drs. Ken Anderson, Jesús San Miguel, Gareth Morgan, and Joan Bladé.

MEET THE BOARD

Joseph M. Hogan

President and CEO of GE Medical Systems, Joe Hogan is an accomplished and admired business leader. Personally touched by his sister's 7 year struggle with multiple myeloma, he is also someone wholeheartedly committed himself to helping all patients and families affected by multiple myeloma. He plans to bring these two roles, businessman and brother, to the MMRF Board as its newest member this fall.



"I was obviously drawn to working with the MMRF because of my personal connection to multiple myeloma and my understanding of the challenges it presents to those who face it; but I was also drawn to the foundation because of its level of professionalism and organization."

Joe will add to the foundation's level of professionalism by bringing his strong business background to the board. His career at GE spans 18 years and a series of leadership roles in sales, marketing and product development in various segments of the company. Now, as CEO of GE Medical Systems, Joe has developed a keen understanding of how emerging medical technologies are successfully incorporated into clinical settings with the help of university-based research and strong financial investment. It is a business model that fits directly in line with the MMRF's mission and goals.

Joe also describes his involvement with the MMRF as a "family affair." His wife Lisa has "been involved since day one" with researching the disease and contributing help to patients and their families. They are both enthusiastic about the work the MMRF does and with "the amazing progress that has been made in treatment options since [their] original awareness of the disease."

The MMRF Board welcomes Joe to our team.

This edition of Myeloma Focus has been generously sponsored by Ms. Joan Lesnick and Dr. Steven Zatz

If you would like to sponsor an edition of Myeloma Focus, contact Craig Robertson at (203) 972-1250 or robertsonc@themmr.org

MYELOMA FOCUS

CONTRIBUTING EDITORS

Shelley Christie
Kathy Giusti
Sara Nichols
Anne Quinn Young
Craig Robertson
Joanna Parzakonis

MEDICAL WRITER

Marie Recine

PRODUCTION

backOfficenyc

ACCELERATING THE SEARCH FOR A CURE

BOARD OF DIRECTORS:

Karen Andrews
Time, Inc
Kathy Giusti
President, MMRF
Ken Anderson, MD
Dana-Farber Cancer Institute
Robert R. Grusky
New Mountain Capital, LLC
Anthony K. Kesman
Alan L. Heller
Baxter International
Joe Hogan
GE Medical
Dana LaForge
Colonnade Financial
William S. McKiernan
CyberSource Corporation
Lynn O'Connor Vos
Grey Healthcare Group
Charles B. Ortner
Proskauer Rose, LLP
Robert Wolf
UBS Warburg
William Willson III
Wilson, Meany, Sullivan
Donna Zaccaro
Multimedia Producer

EXECUTIVE DIRECTOR

Scott Santarella

The Multiple Myeloma Research Foundation

3 Forest Street
New Canaan, CT 06840
Telephone (203) 972-1250
Fax (203) 972-1259
E-mail: info@themmr.org
Visit our website at

<http://www.multiplemyeloma.org>

The information herein is not intended to replace the services of trained health professionals (or to be a substitute for medical advice.) You are advised to consult with your healthcare professional with regard to matters relating to your health, and in particular, regarding matters which may require diagnosis or medical attention.

Thank You

Thank You to All of Our Generous Spring Annual Appeal Donors

The MMRF 2003 Spring Annual Appeal received a record-setting show of support. At the time of print, over \$90,000 was raised by more than 750 generous donors. These amazing results put the MMRF in a great position to exceed their 2003 appeal goal of \$200,000. With the Fall appeal hitting mailboxes in late October, we have an excellent chance to surpass our goal this year.

Kathy Giusti, MMRF President, is overwhelmed by the tremendous kindness of the hundreds of corporations and individuals who supported the drive. "I am so touched by the dedication and generosity of the countless people who continue to support our efforts. We at the MMRF are so thankful to all of those wonderful individuals and companies who continue to move our efforts forward and are helping us to move closer to finding a cure for this disease."

If you would like to join the legions of supporters who have donated to the appeal, please call the MMRF at (203) 972-1250 or go to www.multiplemyeloma.org

President's Club (\$2,500+)

Dr. Steven Zatz &
Ms. Joan Lesnick
Mr. Stuart Kuritsky
Suzy Shechtman
Elaine & Perry Snyderman

Platinum (\$1,000-2,499)

Mr. and Mrs. Theodore H. Brodie
Ms. Myrtle Bruce
Mr. & Mrs. William Butler
Mr. & Mrs. William Covey
Mr. & Mrs. David Fink
Valerie & Mark Friedman
Mr. & Mrs. Edward Gannon
Mr. & Mrs. Peter H. Heerwagen
W. S. Lipschutz & Lynnelle Jones
Ms. Diana Murphy
Mrs. Loretta Peavey
Mr. & Mrs. David W. Spahn
Mrs. Nancy R. Wadhams
Mrs. Nancy Wittendorfer

Gold Sponsor (\$500-999)

Mr. & Mrs. Norman Bergeron
Mr. & Mrs. William S. Brown
Mr. & Mrs. Tom Corbett
Mr. & Mrs. Dana Craaybeek
Mr. & Mrs. Scott Dudley
Mr. & Mrs. Richard C. Edwards
Mr. & Ms. Frank Elmasry
Mr. Walter W. Hess, Jr.
Mr. Brett Himes &
Ms. Annette Severiens
Mr. Howard Honigfeld
Mr. & Mrs. Richard L. Kraner
Mr. & Mrs. John A. McNeice Jr.
Mr. Ross Mongiardo

Van Der Moolen Specialists USA
Mrs. Jeane Owen
Ms. Nancy Rasmussen
Mr. Lawrence Reynolds
Ms. Laura Roe
Mr. Amaury J. Rzad
Dr. & Mrs. Stefan J Rzad
St. Teresa School
Mr. Thomas Talbert
Doug & Helen Towey
Ms. Betty Wilson
Mr. & Mrs. Peter Woll
The Jewish Communal Fund

Silver (\$250-499)

De Lage Landen
Financial Services
Mr. & Mrs. Gerald Gleason
Mrs. Peggy Pearson
Mr. & Mrs. Sergio Pensotti
Mrs. Ann Purcell
Mr. & Mrs. Timothy Brown
Mr. & Mrs. Jack M. Aiello
Mr. & Mrs. Jeremy Barkann
Mr. Terry Birkholz
Dr. & Mrs. John Boehle
Melanie Brown
Phillip T. Chen
Mr. & Mrs. Thomas N. Chewning
Mr. William H. Clampitt Jr.
Pat & Robin Damiani
Ms. Judith A. Delaney
Mr. Thomas F. Farrell
Ms. Mary Feloney
Mr. Peter Fokas
Mr. & Mrs. Jerry Friedman
Lipo Chemical Co.
Ms. Heather Gaillard
Mr. & Mrs. Norman Halford
Mr. & Mrs. Sidney Henderson
Ed & Brenda Hill- Class of 99'

Mr. Andrew Jaffe
Mr. & Mrs. Robert E.
McCarthy, Jr.
Ms. Christine A. McClay
Ms. Nancy McMillan
Mr. & Mrs. James J. Musel
Mr. & Mrs. Jerry D. Parsons
Ms. Heidi Sandreuter
Mr. Robert Steeneck
Mrs. Evelyn Stock
Mr. & Mrs. James R. Wilson
Mr. Tse-Ming Yang
Dr. & Mrs. Ralph Bray
Mr. & Mrs. Malcolm A. Deam
Larry & Carol Dewell
Mr. & Mrs. Richard Duncan
Mr. & Mrs. Scot Melland
Ms. Pamela Moore
Mrs. Robert C. Underwood

Bronze (\$100-249)

Johanna Canale
Mr. & Mrs. Robert Ercolini
Ms. Audley H. Jones
Ms. Tina Keriazes
Mr. Jon Mccorkell &
Mrs. Dianne Cress-Mccorkell
P.O. & B.I. Packard Trust
Mr. & Mrs. Jim Robertson
I.J. Adatto
Mr. & Mrs. Paul Allen
Ms. Haryette Altman
Mr. Lowell E. Anderson
Ms. Carol Arcidy
FreelanceAlot, Inc.
Ms. Sherry Arpke
Mr. John Barcalow III
Mr. & Mrs. Michael D. Barkann
Joyce S. Baum
Mr. Harris Belman

Mr. & Mrs. Marco Benavides
Ms. Debra Bender
Ms. Karen Blumenthal
Mr. & Mrs. Harvey Bocian
Mr. Henry Brady
Ambassador Marshall Brement
Norma Brody & Ethel Blitz
Ms. Emily B. Bruno
Mr. & Mrs. Louis E. Buehn, Jr.
Ms. Josephine R. Bump
Ms. Jane Cairney
Mr. & Ms. Eliot M. Capouya
Mrs. Kathryn Chang
Ms. Beverly Chidel
Mr. John W. Church
Louise & Frank Chut, Sr.
Mr. & Mrs. Clayman
Mr. Stephen Cohen &
Mrs. Carol Fishman
Ms. Miriam Cohen
Mr. William Cook
Ms. Katie Craven
Dr. & Mrs. Daryl F. Daugherty
Mr. Richard Davis
Dr. W. Eugene Davis
Mr. Anthony Desciscio
Mr. & Mrs. Michael Donnelly
Mr. & Mrs. Peter
Drummond-Hay
Mr. Gerald J. Duhon
Mr. Richard Duke
E. Vaughn Dunnigan &
Mark Snyderman
Mrs. Barbara Enloe
Ms. Mary Enroth
Mr. Irving Eskenazi
Mrs. Helene Feinstein
Mr. & Mrs. Leroy Ferrell
Mr. & Mrs. Robert Fischetti
Mr. & Mrs. David Fisher
Mrs. Elizabeth B. Florio
Ms. Mamie D. Folino

Donors

Mr. Thomas A. Frisbie
Mr. & Mrs. Ken Fullerton
Mr. Jack H. Galbraith
Mrs. Carol Garland
Dr. & Mrs. Ronald Geller
Mr. Waldo Gibson
Mr. Edward Glover
Dr. & Mrs. Stuart Goldberg
Mr. Alan R. Goldman
Mr. & Mrs. Robert Greenberg
Ms. Norma Griffith
Ms. Irene Grilli
Mr. & Mrs. Harry G. Hadler
Ms Janet Haff
Ms. Lynne Halliday
Mr. Fred Hathaway
Mrs. Madalena M. Hernandez
Dr. & Mrs. D. G. Hillenbrand
Ms. Betty Hudson
Mr. & Mrs. Marc Isenberg
Mr. & Mrs. Harold Jasmine
Ms. Halloween M. Jeffries
Mr. & Mrs. Wollom A. Jensen
Mr. & Mrs. Arthur Johnson
Mrs. Jane Jordan
Reverend John Kelley
Mr. & Mrs. Wolf D. Knappe
Mr. & Mrs. Gene Kofke
Mr. & Mrs. Stanley Kornblum
Dr. Ed Koschmann
Dr. Joseph M. Lane
Mrs. Kathy Lassen
Ms. Tesair Lauve
John & Mary P. Lennon
Dr. Joseph Lerner
Mr. David Levine
Mr. & Mrs. John P. Lucas
Mr. & Mrs. Scott Lyman
Mr. & Mrs. Allan R. Maier
Mr. & Mrs. Thomas Malone
Mrs. Fred J. Maroon
Ms. Wendy Martin
Dr. Charles Wayne Martin
Mr. & Mrs. Daniel Martinez
Mr. & Mrs. Richard Mayo
Mr. & Mrs. Gerald Mc Lain
Mr. & Mrs. Gary L. McMullin
Mr. & Mrs. Vincent McSherry
Evalyn & Rick Merrick
Ms. Elena Merrick
Ms. Barbara Miller
Mr. & Mrs. Ted H. Moore
Mr. Darrell Murray
Ms. Sharon L. Neste
Mr. & Mrs. James Nicoletto
Mr. Timothy Novacic
Ms. Monika Novograd
Mr. & Mrs. Daniel Okun
Ms. Dorothy Oman

Dr. Miguel Ondetti
Mr. Donald O'Neill
Mr. & Mrs. Osowski
Mr. & Mrs. Lyman Ostlund
Mr. & Mrs. Lawrence Palma
Mr. & Mrs. Joseph Pascale
Mr. Robert Pease
Vicki Pelletier
Mr. & Mrs. Solomon Peltz
Bruce Pichoff M.D.
Mr. & Mrs. Dale Pyeatt
Mrs. Mary Radsavage
Mr. Robert J. Rafferty
Mr. Charles Reich
Mr. & Mrs. Charles Reinwald
Edna Remson
Mr. Roger Reuther
Mr. & Mrs. Milton Riseman
Mr. & Mrs. Gerald Roberts
Mr. & Mrs. Sander Ross
Mrs. Jonette Rukstad
Ms. Rosalee Saikley
Mr. & Mrs. Mark Salton
Mr. & Mrs. Roger Salvesen
Ms. Lisa Santos
Mr. Herbert Schreib
Ms. Mildred Schwartz
Mr. & Mrs. Jerome A. Seidman
Mr. & Mrs. Jon Sharma
Mr. & Mrs. Regan G. Shea
Mr. & Mrs. Stan P. Shreve
Mr. Phillip Siegel
Charles Simberg
Mr. & Mrs. Robert M. Simmons
David & Mary R. Simmons
Mr. & Mrs. Anthony Sinacori
Mr. & Mrs. David A. Slack
Mr. Paul Smith
Ms. Vicki Staugaard
Mr. James Stauner
Mr. Robert Stephens
Mrs. Barbara Stevenson
Mr. Stephen Swan
Ms. Elizabeth Thanos
Mr. Herbert Tischler
Mrs. Shirley Toombs
Ms. Germaine Traczyk
Mr. & Mrs. Peter M. Ungaro
Mr. & Mrs. James E. Vincent
Mr. James Voss
Mr. & Mrs. Fred Wallace
Mr. James Walsh
Mr. Robert Wax
Mr. & Mrs. John P. White
Dr. Francis Wilks
G.H. Williams
Mr. & Mrs. Barry Wilson
Mrs. Lillian Womack
Mr. & Mrs. David L. Zabkowicz

Dr. Jerome B. Zeldis &
Dr. Sharon W. Stamm
Hefez & Sons, Inc.
Civitan Club of
Meriden/Wallingford, Inc.

Friend
(\$50-99)

Mr. James Dolan
Mr. & Mrs. Nicholas Conte
Ms. Elaine Fineman
Mrs. Linda Hillringhouse
Ms. Amanda Kramer
Buddy McAuliffe
Ms. Joyce Abrams-Ross
Mrs. Patricia Albanese
Ms. Gale Albright
Richard & Mary Jo Ambury
Mr. Carl Anderson
Mr. & Mrs. Roy Anderson
Ms. Jane Anton
Mr. & Mrs. Joseph Bachmann
Mr. Michael Baker, Sr.
Mrs. Janet Baker
Mr. & Mrs. Robert K. Barber Sr.
Mr. & Mrs. Darrell Barstow
Ms. Joan Bass
Mr. Bryan Bean
Mrs. Charlene Bloom
Mr. & Mrs. William Bombeck
Mr. & Mrs. Stuart Bookman
Mr. Wayne Boots
Mr. & Mrs. David A. Borchard
Mr. & Mrs. David L. Bowen
Mr. Donald Bruegman
Mrs. Priscilla Bruno
Mr. & Mrs. Roger M. Buffett
Mrs. Renate Burket
Ms. Martha E. Campbell
Mr. & Mrs. James Carollo
Mr. Mario Cavallaro
Mr. & Mrs. John Chambers
Mr. Irving K. Chann
John Chow
Mr. & Mrs. Robert Ciampa
Mrs. Barbara A. Cichowski
Ms. Vitina T. Cimilluca
Dr. & Mrs. Stephen Cole
Mr. James Coogan
Mr. & Mrs. Alan Corey
Mr. Roger Corliss
Mr. & Mrs. John Craparotta
Mrs. Frances Daley
Mr. Pete Damico
Ms. Geraldine De Rose
Ms. Angie M. De Stasio
Mr. & Mrs. Patrick Devaleria
Mr. & Mrs. Dimick

Ms. Jill Dix
Mrs. Patty Dodd
Mr. & Mrs. K.
Christopher Doehring
Mrs. Mary P. Donnelly
Ms. Susan L. Doyle
Mr. Thomas Droege
Ms. Lisa Dvorak
Mr. & Mrs. Gerald Eddington
Ms. Eileen Edwards
Mr. & Mrs. Marion Eipperle
Mr. & Mrs. Charles J. Eiseman
Mr. & Mrs. Bruce Eisen
Ms. Suzanne Eller
Mr. Dick Endres
Mr. & Mrs. Alan Finkelstein
Ms. Barbara Finney
Stephanie & John T. Fisher
Mr. George R. Francis
Ms. Jane L. Freudenberg
Mr. & Mrs. J. Robert Fryer
Mr. & Mrs. Ralph Gage
Mr. Joseph A. Gallucci
Ms. Sharon Ganley
Mr. & Mrs. Frederick Gelberg
Ms. Jane M. Gerber
Carmel Giambattista
Ms. Enid J. Golinkin
Mr. Robert Greenberg
Mrs. Nancy Greenley
Mr. & Mrs. John W. Groover
Mr. & Mrs.
Frederick J. Hansberry
Mr. John W. Harper
Mr. Gordon Helms
Mr. & Mrs. R. Holzman
Dr. & Mrs. John P. Honabarger
Mr. Stephen Huber
Ms. Debi Isreal
Miss Jill Jefferson
Mr. & Mrs. Harold Jones
Mr. & Mrs. Leon H. Kaplan
Mr. & Mrs. Ira Katz
Mr. Donald L. Keeler
Ms. Jean Keith
Mr. & Mrs. G.J. Kiel
Mr. James Chi-Ming Koo &
Ms. Linda S. Berman
Joseph Kopchia
Mr. & Mrs. Morton Kotkin
Dean C. Kraras
Dr. Arnold Kupec
Mr. & Mrs. Leo Larson
Mr. & Mrs. Neville W. Lawton
Mr. & Mrs. Herbert Levin
Ms. Anne Levin
Mr. & Mrs. Fred Lichtstein
Barb & Phil Lindblad
Mr. Gabriel Lo Sapio

Donors

Ms. Maredda L. Magnus
Ms. Rose Manuel
Mr. & Mrs. Charles Martz
Mr. Norman P. Matthews
Terry & Marla Mazer
Ms. Tara McCabe
Mr. Bruce McElwee
Ms. Inez McGoron
Mr. Leon McKeen
Mr. & Mrs. Cyrus Lee McKeithan
Mr. Joseph M. Medwetz
Ms. Clotilde A. Meillon
Mr. & Mrs. Mark A. Messaglia
Ms. Anne Middleton
Mr. Katsumi Mifune
Ms. Berenice M. Miller
Mr. & Mrs. Jesse Miller
Ms. Barbara Monaghan
Mr. & Mrs. Franklyn H. Moore
Mr. James Morrissey
Mr. & Mrs. Melvin Navone
Ms. Dorothy L. Nelson
Mr. & Mrs. Viktor Nevik
Ms. Trang Ngo
Mr. & Mrs. Fred E. O'Hearn
Ms. Elizabeth Olson
Mr. Robert L. Pannell
Mr. Phillip Patton
Robert & Kimberly V. Perini
Mr. & Mrs. John P. Perrigo
Ms. Olive Phillips
Mr. Frank Phillips
Mr. & Mrs. Sammy Piotrkowski
Ms. Cecilia Piper
Dr. Alon Prywes
Mrs. Judy Putnam
Mr. & Mrs. Marvin Rafe
Mr. Jonathan L. Raymond
Ms. Diana Richards
Ms. Marie-Louise Roberts
Mr. & Mrs. Ralph Rosenberg
Mr. & Mrs. Garland Roulston
Mr. & Mrs. Joseph L. Sabadics
Mr. Ray Samuelson
Mr. & Mrs. You Sung Sang
Mr. Ronald Schneider
Stewart Schulman
Mr. & Mrs. William W. Sellers
Ms. Nancy Sessions
Ms. Pearl Shaffer
Ms. Michelle Shanika
Peggy Shealy
Mrs. Sandra Shedlin
Mr. & Mrs. Julien Shoemaker
Mr. & Mrs. Thomas Sisk
Mr. Larry Slivka
Ms. Valerie M. Smith
Mr. & Mrs. William J. Speranza
Mrs. Fay D. Stair

Mr. & Mrs. Ira Starr
Mrs. Linda Faye Starr
Ms. Claire Steckler
Mrs. Rosalie A. Stinson
Mr. & Mrs. Steven Strauss
Ms. Patricia Stump
Mr. & Mrs. Seymour Tabacoff
Mr. & Mrs. Harry Tankus
Dr. & Mrs. Thomas J. Tax
Mr. & Mrs. Paul Tyler
Mr. & Ms. John A. Ulrich
Mr. & Mrs. Stephen J. Vandegraaf
Ms. Louise Wagner
Mr. & Mrs. Patrick Wagner
Mr. & Mrs. Lewis Wallace
Mrs. Margaret Wankoff
Mr. & Mrs. Daniel Warner
Mr. Phillip L. Westine
Ms. Mae White
Mr. & Mrs. Chester Whiteman
Ms. Nancy Whittington
Mr. & Mrs. Don K. Wieneke
Ms. Kristin Wildermann & Mr. Jeffrey P. O'Connor
Robert & Janet Wildman
Ms. Rosemarie Woischke
Mr. William Wright
Ms. Mary Wright
Mr. Robert J. Young
Mr. Eugene Zucker
Medi-Rec Foundation

Supporter (\$10-49)

Mr. & Mrs. Paul A. Flaherty
Ms. Julia Abramovich
Ms. Susan L. Carr
Mr. Jack R. Dudley
Mr. Garrett K. LaForge
Ms. Jo-Anne Morley
Mr. & Mrs. Hank Schroeder
Ms. Geraldine Shafer
Ms. Christine Shatto
Ms. Arleen Simmons
Mrs. Kay Backus
Mr. & Mrs. Darrin S. Baim
Ms. Annette Balfour
Shirley Baughman
Mr. & Mrs. Leo Beck
Mrs. Lisa Becker
Mr. & Ms. Paul W. Bennett III
Ms. Catherine J. Bernstein
Mr. & Mrs. Robert S. Berziga
Mr. Ronald H. Billson
Col. & Mrs. Ronald Blake, (ret)
Ms. Angela Block
Ms. Christine Boukhanian
Mrs. Rita Bourdon
Mr. & Mrs. William Boyd

Mr. & Mrs. Robert W. Bradham
Mr. & Mrs. Oran L. Broome
Ms. Donna R. Bruneau
Mr. James Butler
Catherine Callahan
Ms. Edna Carter
Mrs. Jean Chapman
Mr. Lonnie Christiansen
Dr. Mel S. Citrin
Mr. & Mrs. Richard Collins
Mr. & Mrs. Walter Colterjohn
Mr. Mel Copeland
Mr. Frank Coppola
Laroy Crew
Mrs. Marjorie Crute
Mr. & Mrs. Robert K. Dann
Mr. & Mrs. Dominick DeLorio, Jr.
Mrs. Alma Denton
Ms. Roberta Donahue
Allan J. Doody
Mr. & Mrs. Stephen E. Dunn
Mrs. Barbara Eberhardt
Mr. & Mrs. Irving Edelstein
Mr. Allan Eisel
Ms. Ardella English
Lynn & David Euler
Mr. & Mrs. Gary S. Farber
Mrs. Maureen Farrell
B.J. Sterioti-Ferry
Mr. & Mrs. Charles A. Fleming
Artemis Fokas
Ms. Bernice Frank
Mr. & Mrs. James Frerer
Zoe Ganos
Mr. & Mrs. Dale E. Gatza
Ms. Rosa Giancaspro
Mr. & Mrs. Stanley Gipp
Mr. & Mrs. Calvin Goldberg
Mrs. Joan Gore
Mrs. Edith M. Grasser
Ms. Gene Grassi
Mrs. Norma Griebel
Mr. Richard Gross
Mr. & Mrs. Herbert Guthrie
Mr. & Mrs. C. Clay Haden
Ms. Mary Haley
Ms. Dorothy Harvey
Ms. Muriel Hawthorne
Ms. Ruth Holland
Ms. Lucille S. Holton
Judy & Jerry Honig
Ms. Rosanne Iwanicki
Mr. & Mrs. Allen I. Janis
Ms. Janice Jantz
Mr. Robert Johnston
Mrs. Geneva Jones
Mr. Stephen Jones
Mr. Neal Kane
Ms. Florence Kaufman

Mr. & Mrs. David Kealler
Ms. Dorothy C. Kelly
Mr. & Mrs. Francis Kennedy
Mr. & Mrs. Michael J. Kenny
Ms. Rose M. Krajcar
Ms. Joyce Kreiger
Ms. Phyllis Kuhls
Mr. & Mrs. Ken Landseadel
Mr. & Mrs. Glenn Lindquist
Mrs. Nancy L. Lowe
Ms. Pauline Lundgren
Ms. Shirley Lustig
Mrs. Mary Mahler
Mr. & Mrs. Alan W. Manning
Mr. & Mrs. Harry Mark
Ms. Eleanor Martin
Ms. Tosca Maria Massoni
Ms. Susan Mazarr-Proo
Mr. Ronald Miller
Mr. Lloyd S. Mittenthal
Mr. & Mrs. William Morgan
Ms. Beverly Morrison
Mr. Murray Mussman
Mr. & Mrs. Charles Nearing
Mr. & Mrs. Gary H. Neems
Mr. & Mrs. John Nesci
Mr. Sam Newman
Mr. & Mrs. Robert Nolte
Mr. Jack E. Oden
Mr. & Mrs. Robert W. Paulsen
Mr. & Mrs. Elwin Pearson
Ms. Lynn Peters
Ms. Virginia Porter
Mr. Dominick Puliafio
Mr. & Mrs. Eugene E. Reardon
Virginia & Paul Rehorst
Ms. Ann Marie Rierison
Mr. Rafael Romo
Mr. Ken Rotunno
Mr. & Mrs. Stephen Rozzi
Mr. & Mrs. John Russell
Mr. Robert W. Russell
Mr. & Mrs. Michael J. Russman
Mr. Brendan J. Rynn
Francis F. Sabella
Ms. Diana Sanchez
Ms. Hilda M. Scheinhorn
Mr. Ed Schneiders
Mr. & Mrs. James H. Schulman
Mr. Albert Schwandt
Mr. Sidney Shain
Mr. & Mrs. Stephen A. Shaw
Mr. & Mrs. William E. Shelton
Leslie Skolonis
Ms. Patricia A. Snyder
Mr. & Mrs. Kenneth R. South
Mrs. Genevieve St. Germain
Ms. Elizabeth R. Stoker
Mr. & Mrs. Carey M. Surratt

Donors

Mrs. Shirley Tegge
Mr. & Mrs. Stanley L. Tezyk
Mr. James Thorpe
Mr. & Mrs. Hollis Tinsler
Mr. & Mrs. Richard E. Urban
Mr. & Mrs. Edwin Vanderlaan
Mr. Gerald H. Wagman
Mrs. Linda Wakefield
Mrs. Patricia Wallace-Christian
Ms. Pauline Ward RN
Mrs. & Mrs. Warren
Ms. Margie C. Watson
Mr. & Mrs. Richard Weiner
Ms. Beatrice Weinreich
Mrs. Anne White
Mr. & Mrs. Gary D. White
Mrs. Rose Wirth
Mr. Ray Wischer
Mr. & Mrs. W.A. Wood
Mr. & Mrs. Forrest L. Wootten
Mr. & Mrs. Walter Worsch
Mr. & Mrs. Howard L. Ziff
Ms. Nelda Akes
Mr. & Mrs. Bruce Barritt
J. M. Berry
Ms. Vicki S. Bloom
Mr. Donald Bolar
Ms. Mary Crean & Mr. Steven
Holm-Hansen
Elaine DiRocco
Ms. Mary Domnick
Mr. & Mrs. Robert J. Gianni
Ms. Rosalind Glassman &
Mr. Al Tarantal
Mr. Jim Hawkinson
Mr. & Mrs. Paul Heyman
Mr. & Mrs. M. William Jacunski
Mr. Roy Jeffrey
Anna Keller, in memory of my
father Joseph Steriotti
Mrs. Pam Lubaszewski
Mr. & Mrs. J. Thomas
Manuguerra
Mr. William Richardson
Ms. Sharon Roeschen
Mr. Otto Rogale
Mr. & Mrs. Eugene Saus
Mr. & Mrs. John J. Scharf
Mr. Fred Sealey
Mr. & Mrs. John Shannon Jr.
Mr. & Mrs. Virgil Smith
Dr. & Mrs. Allen Spak
Mr. & Mrs. Bob L. Victor
Mr. Robert West
Mr. & Mrs. Paul Horowitz
Ms. Betty Bennett
Judy Bouloubasis
Mrs. Jean R. Bradley
Ms. Stella Culver
Mr. & Mrs. Gordon Fitch

Ms. Blanche Levine
Mr. John E. Mcnamara
Mrs. Helen A. Niski
Mr. & Mrs. Charles Shafer
Mr. & Mrs. John Sterenberg
Ms. Judith A. Wallace
Ms. Eileen Wratchford
Mr. & Mrs. Robert L. Ackroyd
Ms. Kim Bagley
Geri & Phil Barnett
Mr. & Mrs. Peter Beale
Dianne Elkins
Ms. Sylvia Brown
Mr. John Chittick
Martha M. Czok
Ms. Ann M. Davis
Mr. & Mrs. Joseph P. Durkin
Max Fischer
Mr. Victor Gallino
Mrs. Sue Gibbs
Mrs. Angela Gulko
Ms. Jane Isolde Ferguson & Mr.
John Ferguson
Mr. Russell K. Ivinjack & Ms.
Katherine L. Rizzolo
Mr. William Lehnert
Mr. Richard Lewis
Mrs. Magaly Llaguno
Mrs. Belinda Lockett
Ms. Lisa K. Mark
Mr. & Mrs. Ott Mathias
Mr. & Mrs. John C. Myers
Kenneth & Ligia Niosi
Mrs. Geraldine O'Brien
Mr. David Oliver
Mr. & Mrs. Jacob Pleeter
Ms. S. Joan Popejoy
Mr. & Mrs. Robert F. Prentiss
Ms. Amy Prentiss
Mr. & Mrs. John Ricco
Mr. & Mrs. Nathan Rosen
Ms. Maria Rotondo
Mr. Paul Rourke
Dr. & Mrs. Leonard Rozin
Ms. Edna Rubel
Dr. & Mrs. Dudley Shultz
Mrs. Miriam R. Simon
Ms. Nancy B. Townsley
Ms. Karla Vidis
Mr. & Mrs. Jack Wahlgren
Mr. & Mrs. Thomas F. Wall
Mr & Mrs Lindy Ward
Ms. T. Wasko
Ms. Nellie O. Weeks
Ms. Laura Williams
Mr. & Mrs. Robert Zuczek

DATES TO REMEMBER

September 14, 2003
Chicago, IL

MMRF Race for Research
Contact: Shelley Christie

October 2 & 3, 2003
Toronto, Ontario

MMRF Institutional Insights.
Contact: Sara Nichols

October 5, 2003
Atlanta, GA

MMRF Race for Research
Contact: Shelley Christie

October 25, 2003
Greenwich, CT

MMRF Friends for Life Fall Gala
Contact: Craig Robertson

November 5 & 6, 2003
Chicago, IL

MMRF Institutional Insights
Contact: Sara Nichols

November 13 & 14, 2003
Tampa, FL

MMRF Institutional Insights
Contact: Sara Nichols

November 16, 2003
Washington, DC

MMRF Race for Research
Contact: Shelley Christie

December 6-9, 2003
San Diego, CA

45th Annual American Society of Hematology
(ASH) meeting

December 18, 2003
Teleconference
"Update from ASH"

For more information, please call
(203) 972-1250 or visit
www.multiplemyeloma.org/events

email:
Shelley Christie: christies@themmrf.org
Sara Nichols: nicholss@themmrf.org
Craig Robertson: robertsonc@themmrf.org



MMRF
3 Forest Street
New Canaan, CT 06840

Accelerating the Search for a Cure

NonProfit Org.
US Postage
Paid
New Canaan, CT
Permit No. 58

MMRF NYC Awards Dinner

Story on Page 1



Long-time MMRF supporters, Carol Webb (L) and Mary McGovern (R) of Ortho Biotech, join Kathy Giusti at awards dinner.



Angie Minnick, Myeloma Mentor and patient, pictured with Dr. Sundar Jagannath, NYC Awards Dinner Honoree.